Sarcoidosis after Alemtuzumab therapy: Is Alemtuzumab posing a threat to its patients?

##plugins.themes.themeTen.article.main##

Misbah Nizamani

Keywords

monoclonal antibody, Sarcoidosis

Abstract

Sarcoidosis is a multi-system disorder characterized by the formation of non-caseating granulomas. It is a disorder of unknown etiology. Interferon-induced sarcoidosis is a well-known phenomenon. However, in the past few years, few cases have come forward in which after treatment with a monoclonal antibody, Alemtuzumab, patients developed sarcoidosis. This antibody targets the pan-lymphocyte CD52 antigen found on both human lymphoid and myeloid cells and is used in the treatment of Relapsing Remitting Multiple Sclerosis, leukemia, etc. Patients, in these cases, after a few years of treatment developed sarcoidosis but fortunately responded well to the treatment, if needed.

Abstract 0 | PDF Downloads 0

References

1. Doyle MK, Berggren R, Magnus JH. Interferon-induced Sarcoidosis. J Clin Rheumatol. 2006 Oct;12(5):241-8. doi: 10.1097/01.rhu.0000240035.67652.9d.
2. Graf J, Ringelstein M, Lepka K, et al. Acute Sarcoidosis in a multiple sclerosis patient after Alemtuzumab treatment. Mult Scler. 2018 Nov;24(13):1776-1778. doi: 10.1177/1352458518771276. Epub 2018 Oct 11.
3. Willis MD, Hope-Gill B, Flood-Page P, et al. Sarcoidosis following Alemtuzumab treatment for multiple sclerosis. Mult Scler. 2018 Nov;24(13):1779-1782. doi: 10.1177/1352458518790391. Epub 2018 Oct 11.
4. Erlich-Malona N, Cahill J, Chaudhry S, Martin J, Rizvi S. Cardiac Sarcoidosis requiring ICD placement and immune thrombocytopenia following Alemtuzumab treatment for multiple sclerosis. Mult Scler Relat Disord. 2021 Jan;47:102599. doi: 10.1016/j.msard.2020.102599. Epub 2020 Oct 28.
5. Thachil J, Jadhav V, Gautam M, et al. The development of Sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution. Br J Haematol. 2007 Aug;138(4):559-60. doi: 10.1111/j.1365-2141.2007.06687.x. Epub 2007 Jun 22.
6. Rezvany MR, Tehrani MJ, Karlsson C, et al. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol. 2006 Nov;135(4):475-85. doi: 10.1111/j.1365-2141.2006.06324.x. Epub 2006 Sep 22. PMID: 16995884.